Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
Top Cited Papers
- 1 November 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (31), 4730-4739
- https://doi.org/10.1200/jco.2009.27.7665
Abstract
We have analyzed the outcome of mycosis fungoides (MF) and Sézary syndrome (SS) patients using the recent International Society for Cutaneous Lymphomas (ISCL)/European Organisation for Research and Treatment of Cancer (EORTC) revised staging proposal. Overall survival (OS), disease-specific survival (DSS), and risk of disease progression (RDP) were calculated for a cohort of 1,502 patients using univariate and multivariate models. The mean age at diagnosis was 54 years, and 71% of patients presented with early-stage disease. Disease progression occurred in 34%, and 26% of patients died due to MF/SS. A significant difference in survival and progression was noted for patients with early-stage disease having patches alone (T1a/T2a) compared with those having patches and plaques (T1b/T2b). Univariate analysis established that (1) advanced skin and overall clinical stage, increased age, male sex, increased lactate dehydrogenase (LDH), and large-cell transformation were associated with reduced survival and increased RDP; (2) hypopigmented MF, MF with lymphomatoid papulosis, and poikilodermatous MF were associated with improved survival and reduced RDP; and (3) folliculotropic MF was associated with an increased RDP. Multivariate analysis established that (1) advanced skin (T) stage, the presence in peripheral blood of the tumor clone without Sézary cells (B0b), increased LDH, and folliculotropic MF were independent predictors of poor survival and increased RDP; (2) large-cell transformation and tumor distribution were independent predictors of increased RDP only; and (3) N, M, and B stages; age; male sex; and poikilodermatous MF were only significant for survival. This study has validated the recently proposed ISCL/EORTC staging system and identified new prognostic factors.Keywords
This publication has 39 references indexed in Scilit:
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Gender‐specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthoodInternational Journal of Cancer, 2009
- The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomasBritish Journal of Dermatology, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and stagingLeukemia & Lymphoma, 2006
- Prognostic factor analysis in mycosis fungoides/Sézary syndromeJournal of the American Academy of Dermatology, 1999
- A Prognostic Score for Advanced Hodgkin's DiseaseThe New England Journal of Medicine, 1998
- Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the working formulation of non-Hodgkin's lymphomas for clinical usageCancer, 1994
- Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytesCellular Immunology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958